Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS
· Delayed Price · Currency is USD
0.0500
0.00 (0.00%)
Apr 28, 2026, 3:55 PM EST
Lipella Pharmaceuticals Revenue
Lipella Pharmaceuticals had revenue of $389.78K in the twelve months ending September 30, 2025, down -19.39% year-over-year. In the year 2024, Lipella Pharmaceuticals had annual revenue of $536.36K with 19.29% growth.
Revenue (ttm)
389.78K
Revenue Growth
-19.39%
P/S Ratio
0.59
Revenue / Employee
64.96K
Employees
7
Market Cap
231.04K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Helix BioMedix | 2.07M |
| Regen BioPharma | 236.56K |
| THC Farmaceuticals | 18.52K |
| GB Sciences | 97.24K |
| CNBX Pharmaceuticals | 40.64K |
| Sorrento Therapeutics | 64.27M |
Lipella Pharmaceuticals News
- 4 weeks ago - Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11 - GlobeNewsWire
- 7 months ago - Lipella Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025 - Transcripts
- 8 months ago - Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus - PRNewsWire
- 11 months ago - Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - GlobeNewsWire
- 11 months ago - Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewsWire
- 11 months ago - Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology - GlobeNewsWire
- 1 year ago - Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” - GlobeNewsWire
- 1 year ago - Spartan Capital Securities, LLC Announces Key February Transactions - GlobeNewsWire